Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 6/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | PNP | P00491 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22631571 | 0.87 | EP300 (0.44) | EP300ADORA2AKMT2AKDM4EALDH1A1 | |
| SCHEMBL21977355 | 0.83 | MAPT (0.49) | EP300MAPK14KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL17554285 | 0.83 | EP300 (0.44) | EP300ADORA2AKMT2AALDH1A1HTT | |
| SCHEMBL27549707 | 0.80 | EP300 (0.42) | EP300KMT2ACYP2D6 | |
| SCHEMBL28888847 | 0.80 | EP300 (0.45) | EP300KMT2ASMN1; SMN2CYP2D6 | |
| SCHEMBL2035525 | 0.80 | F2R (0.48) | EP300KMT2ACYP2D6MEN1 | |
| SCHEMBL2383961 | 0.79 | FGFR1 (0.39) | EP300KMT2AALDH1A1CYP2D6MEN1 | |
| SCHEMBL2341203 | 0.78 | MPO (0.41) | EP300KMT2AKDM4EALDH1A1HPGD | |
| SCHEMBL5265127 | 0.78 | MAPK14 (0.58) | ADORA2AMAPK14KMT2AALDH1A1HPGD | |
| SCHEMBL16446911 | 0.77 | FGFR1 (0.47) | EP300CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 820 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746918-A1 | METHODS OF PREPARING SURFACE MODIFIED VIRAL CAPSIDS | Borea Therapeutics S.r.l. (IT) | 2026-05-27 | — | — | EP | claimed |
| WO-2026102435-A1 | METHODS OF NUCLEIC ACID PROCESSING AND SYNTHESIS | UNIVERSITY OF MASSACHUSETTS (US) | 2026-05-15 | — | — | WO | claimed |
| WO-2026101423-A1 | PHOTOSWITCHABLE CHEMICAL INDUCED DIMERIZATION SYSTEMS FOR CONTROL OF CELLULAR ACTIVITIES WITH LIGHT | WU YAOWEN (SE) | 2026-05-15 | — | — | WO | claimed |
| WO-2026085618-A1 | METHOD OF IMMOBILIZING CAPTURE PROBES TO SOLID PHASES FOR TARGET SUBSTANCE DETECTION | YYZ PHARMATECH INC. (CA) | 2026-04-30 | — | — | WO | claimed |
| EP-4716533-A2 | FLUORESCENT INDICATORS FOR METAL ION DETECTION AS SUBSTRATES FOR A SELF-LABELING ENZYME | Ion Biosciences (US) | 2026-04-01 | — | — | EP | claimed |
| US-12560608-B2 | Detection of molecular associations | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2026-02-24 | — | — | US | claimed |
| EP-4688872-A1 | CLICK-TO-INSTALL GENOME EDITING | The General Hospital Corporation (US) | 2026-02-11 | — | — | EP | claimed |
| US-20250377301-A1 | STABILISED FLUOROPHORES, COMPOSITIONS, METHODS OF PREPARATION, CONJUGATES THEREOF, AND METHODS OF USE | FREISTAAT BAYERN LUDWIG MAXIMILIANS UNIV MUENCHEN (DE) | 2025-12-11 | — | — | US | claimed |
| US-20250333696-A1 | DNA-CHIMERIC ANTIGEN RECEPTOR T CELLS FOR IMMUNOTHERAPY | UNIV ARIZONA STATE (US) | 2025-10-30 | — | — | US | claimed |
| US-20250326723-A1 | Development of an Enzyme-Inhibitor Reaction Using Cellular Retinoic Acid Binding Protein II for One-Pot Megamolecule Assembly | UNIV NORTHWESTERN (US) | 2025-10-23 | — | — | US | claimed |
| WO-2010046067-A1 | IMPROVED ALLELE-SPECIFIC AMPLIFICATION | ROCHE DIAGNOSTICS GMBH (DE) | 2010-04-29 | — | — | WO | claimed |
| US-20100099110-A1 | Allele-Specific Amplification | ROCHE MOLECULAR SYSTEMS, INC. (US) | 2010-04-22 | — | — | US | claimed |
| WO-2010012962-A2 | METHOD FOR DETECTING MEMBRANE PROTEIN INTERNALIZATION | CIS-BIO INTERNATIONAL (FR) | 2010-02-04 | — | — | WO | claimed |
| WO-2009060065-A1 | METHOD OF QUANTIFYING TRANSIENT INTERACTIONS BETWEEN PROTEINS | COVALYS BIOSCIENCES AG (CH) | 2009-05-14 | — | — | WO | claimed |
| EP-2049499-A1 | LABELLING OF FUSION PROTEINS WITH SYNTHETIC PROBES | EPFL Ecole Polytechnique Fédérale de Lausanne (CH) | 2009-04-22 | — | — | EP | claimed |
| EP-1895840-A2 | P2Y6 RECEPTOR AGONISTS FOR TREATING LUNG DISEASES | Inspire Pharmaceuticals, Inc. (US) | 2008-03-12 | — | — | EP | claimed |
| WO-2008012296-A1 | LABELLING OF FUSION PROTEINS WITH SYNTHETIC PROBES | EPFL - ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (CH) | 2008-01-31 | — | — | WO | claimed |
| EP-1882688-A1 | Labelling of fusion proteins with synthetic probes | EPFL Ecole Polytechnique Fédérale de Lausanne (CH) | 2008-01-30 | — | — | EP | claimed |
| US-20070015726-A1 | P2Y6 receptor agonists for treating lung diseases | MERCK SHARP & DOHME LLC | 2007-01-18 | — | — | US | claimed |
| WO-2007002945-A2 | P2Y6 RECEPTOR AGONISTS FOR TREATING LUNG DISEASES | INSPIRE PHARMACEUTICALS, INC. (US) | 2007-01-04 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015726-A1 | P2Y6 receptor agonists for treating lung diseases | P2RY6, P2RY1, P2RY11 | EP300 3997/4885ADORA2A 22/4885MAPK14 4362/4885 |
| US-20250377301-A1 | STABILISED FLUOROPHORES, COMPOSITIONS, METHODS OF PREPARATION, CONJUGATES THEREOF, AND METHODS OF USE | CRY1, MKI67, IK | EP300 4874/4885ADORA2A 384/4885MAPK14 2867/4885 |
| US-12560608-B2 | Detection of molecular associations | APP, SPPL2A, SPPL2B | EP300 3019/4885ADORA2A 3529/4885MAPK14 2894/4885 |
| US-20100099110-A1 | Allele-Specific Amplification | RNGTT, HLA-C, POLL | EP300 4461/4885ADORA2A 354/4885MAPK14 4068/4885 |
| US-20250326723-A1 | Development of an Enzyme-Inhibitor Reaction Using Cellular Retinoic Acid Binding Protein II for One-Pot Megamolecule Assembly | CRABP2, RARB, RARA | EP300 4033/4885ADORA2A 3325/4885MAPK14 4112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.